PIONEER 6 finds oral semaglutide does not add heart risk in type 2 diabetes
A 3,183-person study found the pill form of semaglutide did not increase heart attack or stroke risk in adults with type 2 diabetes, clearing the safety bar a new diabetes drug must pass.
Adults with type 2 diabetes and a high risk of heart problems who took an oral form of semaglutide were no more likely to suffer a major cardiovascular event than those given a placebo, according to the PIONEER 6 results published June 11, 2019, in the New England Journal of Medicine [1]. The tablet reached the US market that September as Rybelsus [3].
Trial design
In all, 3,183 people enrolled and were split at random into 1,591 assigned to once-daily oral semaglutide and 1,592 to a dummy pill, with neither patients nor investigators told who received which [1]. Entry required either an age of 50 or older plus diagnosed cardiovascular or chronic kidney disease, or an age of 60 or older with risk factors but no diagnosed disease. The average participant was 66, and 2,695 people, or 84.7%, belonged to the first, sicker group. Half the participants were followed for at least 15.9 months [1].
The study's aim was narrow. Rather than test whether the drug protects the heart, it was sized to rule out an 80% higher rate of cardiovascular problems than placebo — a noninferiority margin of 1.8 on the upper end of the 95% confidence interval [1].
The cardiovascular numbers
The main measure combined three outcomes: death from heart causes, nonfatal heart attack and nonfatal stroke. It occurred in 61 of 1,591 patients on the drug, or 3.8%, and 76 of 1,592 on placebo, or 4.8%. The hazard ratio was 0.79, with a 95% confidence interval of 0.57 to 1.11, and the trial met its noninferiority threshold (P<0.001) [1].
Taken one at a time: cardiovascular death 15 patients (0.9%) versus 30 (1.9%), hazard ratio 0.49 (95% CI, 0.27 to 0.92); nonfatal heart attack 37 (2.3%) versus 31 (1.9%), hazard ratio 1.18 (95% CI, 0.73 to 1.90); nonfatal stroke 12 (0.8%) versus 16 (1.0%), hazard ratio 0.74 (95% CI, 0.35 to 1.57). Death from any cause was recorded in 23 patients (1.4%) on semaglutide and 45 (2.8%) on placebo, hazard ratio 0.51 (95% CI, 0.31 to 0.84) [1].
None of those component comparisons is precise enough to stand alone. For the combined measure, the confidence interval reaches above 1.0, which means the study cannot show that the drug lowers cardiovascular risk — only that any increase is smaller than the trial was built to detect [1].
Gastrointestinal side effects serious enough to make patients stop treatment were more frequent on the drug. The published abstract does not give those rates, and it also does not report blood sugar or weight changes [1]. Rybelsus prescribing information names nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation as common reactions, each in at least 5% of patients, and carries warnings for pancreatitis, diabetic retinopathy complications, low blood sugar when the drug is combined with insulin or insulin-releasing medicines, kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions and aspiration during anesthesia or deep sedation [3].
Novo Nordisk sponsored the trial, registered as NCT02692716 [1].
Why it matters for patients
Swallowing a tablet is not the same as injecting semaglutide. The injected form is about 89% bioavailable, while the tablet delivers only 1 to 2% of a dose and must be taken once daily in the morning on an empty stomach [2][3]. That difference is why regulators wanted separate heart-safety data before the pill could be sold [1].
The evidence covers a specific group: people with type 2 diabetes who already had cardiovascular disease, kidney disease or multiple risk factors. Adults taking semaglutide only for weight loss were not part of this trial [1], and whether the findings hold over longer periods is not established, since follow-up lasted a median of 15.9 months [1].
How much the tablet improves blood sugar control is not reported in this abstract [1].
What happens next
Novo Nordisk submitted its FDA application for oral semaglutide on March 26, 2019 [3]. Approval came September 20, 2019, making Rybelsus the first oral GLP-1 medicine for adults with type 2 diabetes [3]. On October 17, 2025, the FDA added an indication to reduce the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes, based on this body of research [3]. A second tablet formulation in 1.5 mg, 4 mg and 9 mg strengths was approved December 9, 2024, and renamed Ozempic tablets on January 30, 2026 [3].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.